Stem cell transplantation in acute leukemia

Current Opinion in Oncology

Volumn 10, Issue 1, 1998, Pages 10-16

  Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BUSULFAN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IODINE 131;

ACUTE LEUKEMIA; ALLOGRAFT; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOTRANSPLANTATION; BONE MARROW CELL; CANCER RECURRENCE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL; HISTOCOMPATIBILITY; HUMAN; LEUKOCYTE; MINIMAL RESIDUAL DISEASE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; STEM CELL TRANSPLANTATION; UMBILICAL CORD BLOOD;

EID: 0031975816     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199801000-00003     Document Type: Review

References (37)

1. Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, et al.: Donor leukocyte Infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15:433-444.
2. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O'Bnen S, Khouri I, Gajewski J, Mehra R, et al.: Engraftment of allogeneic hematopoietic progenitor cells with purine analogue-containing chemotherapy: harnessing graft-versus-leukemia without myeloablatlve therapy. Blood 1997, 89:4531-4536.
3. Petersdorf EW, Longton GM, Anasetti C, Martin PJ, Mickelson EM, Smith AG, Hansen JA: The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995, 86:1606-1613.
4. Sierra J, Radich J, Hansen JA, Martin PJ, Petersdorf EW, Bjerke J, Bryant E, Nash RA, Sanders JE, Storb R, et al.: Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1997, 90:1410-1414.
5. Petersdorf EW, Longton GM, Anasetti C, Mickelson EM, McKinney SK, Smith AG, Martin PJ, Hansen JA: Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997, 89:1818-1823.
6. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocci G, Carrier C, Stevens CE, Rubinstein P: Placental blood as a source of hematopoletlc stem cells for transplantation into unrelated recipients. N Engl J Med 1996, 335:157-166.
7. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, Ortega J, Souillet G, Ferreira E, Laporte J-P, et al.: Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997, 337:373-381.
8. Laporte J-P, Gorin N-C, Rubinstein P, Lesage S, Portnoi M-F, Barbu V, Lopez M, Douay L, Najman A: Cord-blood transplantation from an unrelated donor in an adult with chronic myelogenous leukemia. N Engl J Med 1997, 335:167-170.
9. Damiani D, Fanin R, Silvestri F, Grimaz S, Infanti L, Geromin A, Cerno M, Michieli M, Rinaldi C, Savignano C, et al.: Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. Blood 1997, 90:36-42.
10. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Loffler H, Hunter A, Russel NH: Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995, 85:1666-1672.
11. Körbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth AB, et al.: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995, 85:1659-1665.
12. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, Storb R, Buckner CD: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995, 85:1655-1658.
13. Pavletic ZS, Bishop MR, Tarantolo SR, Martin-Algarra S, Bierman PJ, Vose JM, Reed EC, Gross TG, Kollath J, Nasrati K, et al.: Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol 1997, 15:1608-1616.
14. +) in the blood of normal donors. Blood 1997, 89:2586-2595.
15. Anderlini P, Körbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, Howe C, Leitman S, Horowitz M, Gluckman E, et al.: Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997, 90:903-908.
16. Radich J, Gehlyt G, Lee A, Avery R, Bryant E, Edmands S, Gooley T, Kessler P, Kirk J, Ladne P, et al.: Detection of BCR/ABL transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997, 89:2602-2609.
17. Mitterbauer G, Fodinger M, Scherrer R, Knobl P, Jager U, Laczika K, Schwarzinger I, Gaiger A, Geissler K, Greinix H, et al.: PCR-monitoring of minimal residual leukaemia after conventional chemotherapy and bone marrow transplantation In BCR/ABL positive acute lymphoblastic leukaemia. Br J Haematol 1995, 89:937-942.
18. Voncken JW, Kaartinen V, Pattengale PK, Germeraad WTV, Grotten J, Heisterkamp N: BCR/ABL p210 and p190 cause distinct leukemia in transgenic mice. Blood 1995, 86:4603-4610.
19. Radich J, Ladne P, Gooley T: PCR-based detection of unique immunoglobulin V-D-J gene rearrangements In acute lymphoblastic leukemia predicts relapse after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 1995, 1:24-27.
20. Saunders MJ, Tobal K, Keeney S, Liu Yin JA: Expression of diverse AML1/MTG8 transcripts is a consistent feature in acute myeloid leukemia with t(8;21) irrespective of disease phase. Leukemia 1996, 10:1139-1143.
21. Tobal K, Liu Yin JA: Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8;21). Blood 1996, 88:3704-3709.
22. Jurlander J, Caligiuri MA, Ruutu T, Baer MR, Strout MP, Oberkircher AR, Hoffmann L, Ball ED, Frei-Lahr DA, Christiansen NP, et al.: Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996, 88:2183-2191.
23. Meloni G, Diverio D, Vignetti M, Awisati G, Capria S, Petti MC, Mandelli F, Lo Coco F: Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARa fusion gene. Blood 1997, 90:1321-1325.
24. Stein AS, O'Donnell MR, Slovak M, Lee J, Kashyap A, Molina A, Nademanee A, Parker P, Planas I, Snyder DS, et al.: Do cytogenetics predict outcome of autologous bone marrow transplantation (ABMT) for acute myelogenous leukemia (AMD in 1st remission (CR)? [abstract] Blood 1996, 88:485a.
25. Cassileth P, Harrington D, Paietta E, Lazarus H, Appelbaum F, Blume K, Bennett J, Hurd D, Willman C, Slovak M, Wiemik P: Comparison of autologous bone marrow transplant (AUTOBMT) with high-dose cytarabine (HDAC) in adult acute myeloid leukemia (AML) in first remission (CR1): an ECOG intergroup study [abstract]. Proc Am Soc Clin Oncol 1997, 16:89a.
26. Appelbaum FR: Allogeneic hematopoietic stem cell transplantation for acute leukemia. Semin Oncol 1997, 24:114-123.
27. 131l-anti-CD45 antibody plus busulfan/cyclophosphamide in matched related transplants for AML in first remission. [abstract] Blood 1996, 88:142a.
28. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, et al: Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997, 89:3055-3060.
29. Stein AS, O'Donnell MR, Chai A, Schmidt GM, Nademanee A, Parker PM, Smith EP, Snyder DS, Molina A, Stepan DE, et al.: In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. J Clin Oncol 1996, 14:2206-2216.
30. Benyunes MC, Higuchi C, York A, Lindgren C, Thompson JA, Buckner CD, Fefer A: Immunotherapy with interleukin-2 with or without lymphokine activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibililty trial. Bone Marrow Transplant 1995, 16:283-288.
31. Klingemann H-G, Eaves CJ, Barnett MJ, Eaves AC, Hogge DE, Nantel SH, Reece E, Shepherd JD, Sutherland HJ, Phillips GL: Transplantation of patients with high risk acute myelold leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin 2 administration. Bone Marrow Transplant 1994, 14:389-396.
32. Margolin KA, Wright C, Forman SJ: Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells. Leukemia 1997, 9:723-728.
33. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994, 153:1687-1696.
34. Margolin KA, Negrin RS, Wong KK, Chatterjee S, Wright C, Forman SJ: Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev 1997, 157:231-240.
35. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA: Specific human cellular immunity to bcr-abl oncogene derived peptides. Blood 1996, 87:3587-3592. This report, as with Choudhury et al. (Blood 1997, 89:1133-1142), demonstrates that cytolytic T cells can be generated that target specific oncogene-derived peptides and provides the basis for a very specific immunotherapeutic approach in patients undergoing either autologous or allogeneic transplantation.
36. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA: Specific human cellular immunity to bcr-abl oncogene derived peptides. Blood 1996, 87:3587-3592. This report, as with Choudhury et al. (Blood 1997, 89:1133-1142), demonstrates that cytolytic T cells can be generated that target specific oncogene-derived peptides and provides the basis for a very specific immunotherapeutic approach in patients undergoing either autologous or allogeneic transplantation.
37. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche K-O, Andreeff M, Champlin RE: Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxiclty against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997, 89:1133-1142.